UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Nature (London), ISSN 0028-0836, 2016, Volume 534, Issue 7605, pp. 47 - +
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Oncogenes - genetics | Recombinational DNA Repair - genetics | Genomics | Humans | Male | Mutation Rate | Mutation - genetics | Genome, Human - genetics | Breast Neoplasms - genetics | Mutagenesis | DNA Mutational Analysis | DNA Replication - genetics | Genes, BRCA2 | Female | DNA, Neoplasm - genetics | Genes, BRCA1 | Cohort Studies | Gene mutations | Oncology, Experimental | Cancer cells | Breast cancer | Genetic aspects | Research | Cancer | Nucleotide sequencing | Health aspects | Mutation (Biology) | DNA sequencing | Medical colleges | DNA replication | Analysis | Genes | Genetic research | Genomes | DNA methylation | Mutation | Deoxyribonucleic acid--DNA | Index Medicus | Life Sciences | BASIC BIOLOGICAL SCIENCES | Biological Science | Medical and Health Sciences | Medicin och hälsovetenskap | Breast Neoplasms | Klinisk medicin | Medicinsk genetik | Medical Genetics | DNA, Neoplasm | Oncogenes | Basic Medicine | Recombinational DNA Repair | Cell and Molecular Biology | DNA Replication | Clinical Medicine | Medicinska och farmaceutiska grundvetenskaper | Genome, Human | Cancer and Oncology | Cell- och molekylärbiologi | Cancer och onkologi
Journal Article
Breast cancer research and treatment, ISSN 0167-6806, 12/2008, Volume 112, Issue 3, pp. 533 - 543
Phase III | Biomarker | Medicine & Public Health | Advanced breast cancer | Capecitabine | HER2-positive | Oncology | Metastatic breast cancer | Lapatinib | Dual tyrosine kinase inhibitor | Life Sciences & Biomedicine | Science & Technology | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Humans | Middle Aged | Biomarkers, Tumor | Breast Neoplasms - drug therapy | Disease Progression | Antibodies, Monoclonal, Humanized | Neoplasm Metastasis | Fluorouracil - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Aged | Deoxycytidine - analogs & derivatives | Trastuzumab | Protein-Tyrosine Kinases - antagonists & inhibitors | Index Medicus
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 12/2009, Volume 27, Issue 36, pp. 6129 - 6134
Life Sciences & Biomedicine | Oncology | Science & Technology | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Axilla - pathology | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Cyclophosphamide - adverse effects | Young Adult | Antibodies, Monoclonal, Humanized | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Adult | Female | Chemotherapy, Adjuvant | Taxoids - adverse effects | Survival Rate | Lymphatic Metastasis | Breast Neoplasms - drug therapy | Disease-Free Survival | Taxoids - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Aged | Trastuzumab | Epirubicin - adverse effects | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 12/2006, Volume 355, Issue 26, pp. 2733 - 2743
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Gynecology. Andrology. Obstetrics | Mammary gland diseases | Biological and medical sciences | General aspects | Medical sciences | Tumors | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Protein Kinase Inhibitors - adverse effects | Fluorouracil - therapeutic use | Breast Neoplasms - chemistry | Deoxycytidine - therapeutic use | Fluorouracil - adverse effects | Aged, 80 and over | Adult | Deoxycytidine - adverse effects | Female | Receptor, ErbB-2 - antagonists & inhibitors | Heart Diseases - chemically induced | Fluorouracil - analogs & derivatives | Proportional Hazards Models | Breast Neoplasms - drug therapy | Disease Progression | Antimetabolites, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Quinazolines - adverse effects | Survival Analysis | Breast Neoplasms - mortality | Aged | Receptor, ErbB-2 - analysis | Deoxycytidine - analogs & derivatives | Drug therapy | Breast cancer | Gene amplification | Epidermal growth factor | Kinases | Womens health | Cancer therapies | Index Medicus | Abridged Index Medicus
Journal Article
Nature communications, ISSN 2041-1723, 07/2016, Volume 7, Issue 1, pp. 12222 - 12222
Journal Article
The lancet oncology, ISSN 1470-2045, 2013, Volume 14, Issue 1, pp. 64 - 71
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Capecitabine | Drug-Related Side Effects and Adverse Reactions - chemically induced | Humans | Middle Aged | Brain Neoplasms - pathology | Receptor, ErbB-2 - metabolism | Central Nervous System - pathology | Breast Neoplasms - metabolism | Drug-Related Side Effects and Adverse Reactions - pathology | Brain Neoplasms - secondary | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Endpoint Determination | Adult | Deoxycytidine - adverse effects | Female | Quinazolines - administration & dosage | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Brain Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Breast Neoplasms - pathology | Quinazolines - adverse effects | Central Nervous System - drug effects | Aged | Neoplasm Staging | Deoxycytidine - analogs & derivatives | Drug-Related Side Effects and Adverse Reactions - classification | Antimitotic agents | Brain | Care and treatment | Oncology, Experimental | Breast cancer | Metastasis | Research | Antineoplastic agents | Cancer | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2013, Volume 14, Issue 10, pp. 933 - 942
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Antibodies, Monoclonal, Humanized - adverse effects | Humans | Middle Aged | Vascular Endothelial Growth Factor A - blood | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Vascular Endothelial Growth Factor Receptor-2 - blood | Receptors, Estrogen - analysis | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Breast Neoplasms - drug therapy | Bevacizumab | Receptors, Progesterone - analysis | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Adult | Breast Neoplasms - mortality | Female | Aged | Chemotherapy, Adjuvant | Receptor, ErbB-2 - analysis | Breast cancer | Adjuvant treatment | Cancer | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 741 - 748
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Breast Neoplasms - surgery | Predictive Value of Tests | Breast Neoplasms - secondary | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Young Adult | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Neoplasms, Second Primary | Time Factors | Antineoplastic Agents - adverse effects | Aged, 80 and over | Mastectomy | Adult | Female | Chemotherapy, Adjuvant | France | Heart Diseases - chemically induced | Radiotherapy, Adjuvant | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Early Detection of Cancer | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Proportional Hazards Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - mortality | Aged | Infusions, Intravenous | Receptor, ErbB-2 - analysis | Trastuzumab | Antimitotic agents | Care and treatment | Clinical trials | Breast cancer | Product development | Antineoplastic agents | Cancer | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1269 - 1278
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Neoplasm Recurrence, Local - mortality | Bevacizumab | Patient Selection | Dose-Response Relationship, Drug | Neoplasm Recurrence, Local - pathology | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Neoplasm Invasiveness - pathology | Adult | Remission Induction - methods | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Retreatment | Maximum Tolerated Dose | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Genes, erbB-2 - genetics | Survival Analysis | Breast Neoplasms - mortality | Aged | Neoplasm Staging | Medical colleges | Care and treatment | Relapse | Chemotherapy | Breast cancer | Metastasis | Angiogenesis inhibitors | Diseases | Cancer | Index Medicus
Journal Article